Show simple item record

2021-12-25Zeitschriftenartikel
Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility
dc.contributor.authorKresken, Michael
dc.contributor.authorKlare, Ingo
dc.contributor.authorWichelhaus, Thomas A.
dc.contributor.authorWohlfarth, Esther
dc.contributor.authorLayer-Nicolaou, Franziska
dc.contributor.authorNeumann, Bernd
dc.contributor.authorWerner, Guido
dc.contributor.authorStudy Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy
dc.date.accessioned2022-03-21T11:37:50Z
dc.date.available2022-03-21T11:37:50Z
dc.date.issued2021-12-25none
dc.identifier.other10.1016/j.jgar.2021.12.016
dc.identifier.urihttp://edoc.rki.de/176904/9528
dc.description.abstractObjectives: The aim of this study was to evaluate the occurrence of glycopeptide resistance in enterococci and coagulase-negative staphylococci (CoNS) and to determine the susceptibilities of the identified glycopeptide-resistant isolates to dalbavancin. Methods: Twenty-two medical laboratories participated in the study conducted in 2016/17 by the Paul-Ehrlich-Society for Chemotherapy. Each laboratory was asked to collect 30 Enterococcus spp. (limited to Enterococcus faecalis and Enterococcus faecium) and 30 CoNS isolates consecutively from hospitalised patients with a proven or suspected infection. Results: A total of 1285 isolates were collected, comprising 364 E. faecalis, 291 E. faecium and 630 CoNS. No E. faecalis isolates (0%) but 76 E. faecium isolates (26.1%) were vancomycin-resistant, of which 21 showed the VanA type and 55 the VanB type. The proportion of vancomycin-resistant strains among E. faecium isolates from patients in intensive care units (21.6%) was significantly lower than that from patients on regular wards (30.5%). Among the CoNS, 67 isolates (10.6%) were teicoplanin-resistant but none were vancomycin-resistant, with resistance only detected in Staphylococcus epidermidis (12.2%), Staphylococcus haemolyticus (17.9%) and Staphylococcus hominis (13.2%). Dalbavancin at ≤0.25 mg/L inhibited all VanB-type enterococci and 95.5% of teicoplanin-resistant CoNS. Conclusion: The level of glycopeptide resistance in E. faecalis remains very low in Germany but achieved 26% in E. faecium and was >10% in CoNS. Dalbavancin appears to be a feasible option for treating infections caused by VanB-type vancomycin-resistant E. faecium and teicoplanin-resistant CoNS.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectVancomycineng
dc.subjectTeicoplanineng
dc.subjectLipoglycopeptideeng
dc.subjectDalbavancineng
dc.subjectvanAeng
dc.subjectvanBeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleGlycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibilitynone
dc.typearticle
dc.identifier.urnurn:nbn:de:0257-176904/9528-3
dc.type.versionpublishedVersionnone
local.edoc.container-titleJournal of Global Antimicrobial Resistancenone
local.edoc.container-issn2213-7173none
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.sciencedirect.com/science/article/pii/S2213716521002897none
local.edoc.container-publisher-nameElseviernone
local.edoc.container-volume28none
local.edoc.container-year2021none
local.edoc.container-firstpage102none
local.edoc.container-lastpage107none
dc.description.versionPeer Reviewednone

Show simple item record